NCT06161974 - Study of Olutasidenib and Temozolomide in HGG | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2035

Conditions

High Grade GliomaAstrocytomaAstrocytoma, Grade IIIAstrocytoma, Grade IVDiffuse Intrinsic Pontine GliomaWHO Grade III GliomaWHO Grade IV GliomaMetastatic Brain TumorDiffuse Midline Glioma, H3 K27M-MutantThalamus TumorSpinal TumorIDH1 MutationIDH1 R132IDH1 R132CIDH1 R132HIDH1 R132SIDH1 R132GIDH1 R132LOligodendroglioma

Interventions

DRUG

Olutasidenib + TMZ

Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD

Trial Locations (18)

2031

NOT_YET_RECRUITING

Sydney Children's Hospital, Randwick

3720

NOT_YET_RECRUITING

Princess Máxima Center, Utrecht

4101

NOT_YET_RECRUITING

Queensland Children's Hospital, South Brisbane

6000

NOT_YET_RECRUITING

Perth Children's Hospital, Perth

19104

NOT_YET_RECRUITING

Children's Hospital of Philadelphia, Philadelphia

20010

NOT_YET_RECRUITING

Children's National Medical Center, Washington D.C.

27708

NOT_YET_RECRUITING

Duke University Health System, Durham

43235

NOT_YET_RECRUITING

Nationwide Children's Hospital, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

NOT_YET_RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

69120

NOT_YET_RECRUITING

Hopp Children's Cancer Center at NCT Heidelberg (KiTZ), Heidelberg

77030

NOT_YET_RECRUITING

Texas Children's Hospital, Houston

80045

NOT_YET_RECRUITING

Children's Hospital Colorado, Aurora

98105

NOT_YET_RECRUITING

Seattle Children's Hospital, Seattle

02215

NOT_YET_RECRUITING

Susan Chi, Boston

M5G1X8

NOT_YET_RECRUITING

The Hospital for Sick Children (SickKids), Toronto

H4A3J1

NOT_YET_RECRUITING

Montreal Children's Hospital, Montreal

WC1N 3JH

NOT_YET_RECRUITING

Great Ormond Street Hospital, London